By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Helicos BioSciences today reported a 43 percent drop in its third quarter revenues.

In a document filed with the US Securities and Exchange Commission, the sequencing technology and diagnostics firm reported that for the three months ended Sept. 30, it recorded $636,000 in revenues, down from $1.1 million in the year-ago period. Product revenues plummeted to $214,000 from $1.1 million, an 81 percent drop-off. Grant revenues rose to $422,000 from $13,000 a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.